Showing results (21-30 of 50) with videos related to

Sort By:
Pageof 5
Clinical Rheumatology|July 18, 2018
Clinically important neutralizing anti-drug antibodies detected with an in-house competitive ELISAManca Ogrič, Polona Žigon, Katja Lakota, et al.
Inflammatory Bowel Diseases|August 3, 2019
A Population Pharmacokinetic and Exposure-Response Model of Golimumab for Targeting Endoscopic Remission in Patients With Ulcerative ColitisErwin Dreesen, Wannee Kantasiripitak, Iris Detrez, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 4, 2014
Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapyFilip Baert, David Drobne, Ann Gils, et al.
Medicina (Kaunas, Lithuania)|December 23, 2023
Performance of European and American Societies of Gastrointestinal Endoscopy Guidelines for Prediction of Choledocholithiasis in Patients with Acute Biliary PancreatitisŽan Peter Černe, Nejc Sever, Luka Strniša, et al.
International Journal of Molecular Sciences|June 26, 2025
Free and Bioavailable Vitamin D Are Correlated with Disease Severity in Acute Pancreatitis: A Single-Center, Prospective StudyDarko Siuka, Matej Rakuša, Aleš Vodenik, et al.
European Journal of Gastroenterology & Hepatology|November 8, 2008
Acute biliary pancreatitis: detection of common bile duct stones with endoscopic ultrasoundBorut Stabuc, David Drobne, Ivan Ferkolj, et al.
Alimentary Pharmacology & Therapeutics|February 21, 2019
Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel diseaseDavid Drobne, Tina Kurent, Saša Golob, et al.
European Journal of Gastroenterology & Hepatology|August 17, 2021
Ustekinumab concentrations shortly after escalation to monthly dosing may identify endoscopic remission in refractory Crohn's diseaseJurij Hanžel, Matic Koželj, Ana Špes Hlastec, et al.
United European Gastroenterology Journal|July 19, 2019
Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel diseaseJurij Hanžel, Nejc Sever, Ivan Ferkolj, et al.
European Journal of Gastroenterology & Hepatology|August 18, 2020
Endoscopic remission can be predicted by golimumab concentrations in patients with ulcerative colitis treated with the changed labelSebastian Stefanovic, Iris Detrez, Griet Compernolle, et al.
Pageof 5